Abstract
Chemosaturation percutaneous hepatic perfusion (CS-PHP) with melphalan provides selective intrahepatic delivery of high dose cytotoxic melphalan while limiting systemic toxicity through hemofiltration of the hepatic venous blood. The aim of this study was to investigate safety, therapy response and survival of CS-PHP in patients with curatively untreatable liver-dominant metastatic uveal melanoma (UM).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
